Pharos IBio Co (XKRX:388870) Change In Receivables : ₩-38.05 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Change In Receivables?

Pharos IBio Co's change in receivables for the quarter that ended in Mar. 2025 was ₩0.00 Mil. It means Pharos IBio Co's Accounts Receivable stayed the same from Dec. 2024 to Mar. 2025 .

Pharos IBio Co's change in receivables for the fiscal year that ended in Dec. 2024 was ₩-38.05 Mil. It means Pharos IBio Co's Accounts Receivable increased by ₩38.05 Mil from Dec. 2023 to Dec. 2024 .

Pharos IBio Co's Accounts Receivable for the quarter that ended in Mar. 2025 was ₩0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Pharos IBio Co's liquidation value for the three months ended in Mar. 2025 was ₩-1,185.23 Mil.

Pharos IBio Co Change In Receivables Historical Data

The historical data trend for Pharos IBio Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Change In Receivables Chart

Pharos IBio Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

23.09

-4.82

-24.29

28.77

-38.05

Pharos IBio Co Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial										-7.90	5.53	-62.94	27.26	-

Pharos IBio Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-38.05 Mil.

Pharos IBio Co (XKRX:388870) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Pharos IBio Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Pharos IBio Co's accounts receivable are only considered to be worth 75% of book value:

Pharos IBio Co's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0	-	1185.233	+	0.75 * 0	+	0.5 * 0
=	-1,185.23

Pharos IBio Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharos IBio Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR

Website

https://www.pharosibio.com

Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines